Nisha Pandey

Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy

Blood Test Detecting 50+ Cancers May Soon Become A Reality As US FDA Raises No Major Concerns About Its Accuracy

Biotechnology company Grail's vision of detecting more than 50 cancers with one blood test may soon become a reality after it showed promise of a positive outcome with the US Food and Drug Administration staff reviewers.

According to Reuters, FDA has not raised any major concerns yet about the accuracy and of the blood test, Galleri, which is designed to capture signals from more than 50 types of cancer. The promising biomedical technology seems to be closer to a positive regulatory decision.

Ahead of an advisory committee meeting on September 23, <a href="https://www.healthandme.com/health-news/indian-medical-industry-backs-maharashtra-fda-crackdown-on-device-markups-article-156166929" data-type="tilCustomLink">FDA</a> briefing documents were released which said that reviewers had no outstanding questions regarding its accuracy, safety, overall analytical performance, and study design.

However, this does not mean the FDA has approved Galleri. External advisers will now examine whether the available evidence is sufficient to back it and approve the multi-cancer early detection test.

Also read: <a href="https://www.healthandme.com/health-news/from-remdesivir-to-ventilators-covid-patients-died-due-to-hospital-protocols-claims-whistleblower-nurse-article-156198977" data-type="tilCustomLink">From Remdesivir To Ventilators: COVID Patients Died Due To Hospital Protocols, Claims Whistleblower Nurse</a>

Galleri is a type of <a href="https://www.healthandme.com/health-news/panxeon-new-blood-test-offers-hope-for-earlier-pancreatic-cancer-detection-article-156174768" data-type="tilCustomLink">multi-cancer early detection (MCED) test</a>. Instead of searching for one specific cancer, it examines and analyses DNA fragments circulating in the blood for chemical patterns linked with various cancers.

If the test detects a cancer signal, it also attempts to predict where in the body that signal originated, helping doctors decide which diagnostic tests may be needed next.

The test is not meant to replace to existing cancer screening tests such as mammograms, colon cancer screening and cervical cancer screening. It is supposed to be used with existing screening methods for faster and more accurate diagnoses. 

Also read: <a href="https://www.healthandme.com/health-news/lsd-based-treatment-clears-second-phase-3-trial-could-it-be-the-first-new-gad-drug-in-2-decades-article-156196458" data-type="tilCustomLink">LSD-Based Treatment Clears Second Phase 3 Trial: Could It Be The First New GAD Drug In 2 Decades?</a>

No multi-cancer detection test is currently FDA-authorised in the US. Some are available as laboratory-developed tests, but they do not undergo the same premarket approval process.

Grail submitted Galleri for FDA premarket approval in January 2026. The application includes data from <a href="https://www.healthandme.com/health-news/rfk-jr-backed-wolverine-peptide-use-surges-why-are-people-taking-an-unapproved-drug-for-injury-recovery-article-156165458" data-type="tilCustomLink">PATHFINDER 2</a>, a US study involving more than 25,000 participants, as well as data from the large NHS-Galleri trial in the UK.

The FDA's latest briefing documents describe the test as having a favourable benefit-risk profile, but advisers have been asked to consider an important question before making their decision. 

The question is does detecting a cancer signal translate into meaningful clinical benefit for patients? It's important as finding more cancers is not automatically the same as saving more lives.

<h2>Galleri Has Also Faced Questions About Early Detection</h2>

Alzheimer’s Disease: Early Signs, Symptoms, Diagnosis & Prevention Tips

In February, Grail reported that its large UK NHS-Galleri trial did not significantly reduce the combined rate of <a href="https://www.healthandme.com/health-news/new-rna-therapy-for-als-the-disease-stephen-hawking-had-patient-with-rare-motor-neuron-disease-improves-article-156196277" data-type="tilCustomLink">stage III and IV cancers</a>, the study's primary endpoint, across three screening rounds.

Later analyses reported by Grail found reductions in stage IV diagnoses during screening rounds that were held later, but the company also acknowledged that the trial did not show a statistically significant reduction in the combined primary endpoint of stage III and IV cancers.

This is why the FDA's question about whether Galleri should be considered an “early detection” test is particularly crucial.

The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review the application on September 23. The panel's recommendation will help inform the FDA. If authorised, Galleri could become the first FDA-authorised multi-cancer detection test in the US.

Health Conditions A-Z

health

blood-test-detecting-50-cancers-may-soon-become-a-reality-as-us-fda-raises-no-major-concerns-about-its-accuracy

us fda

Grail

galleri

blood test 50 cancers

cancer blood test

US Food and Drug Administration

why-is-trump-administration-testing-drinking-water-for-abortion-pills-epas-controversial-move-explained

Why Is Trump Administration Testing Drinking Water For Abortion Pills? EPA’s Controversial Move Explained

cdc-youth-report-teen-mental-health-suicide-risk-improve-sleep-low-exercise-remain-concerns

CDC Youth Report: US Teen Mental Health, Suicide Risk Improve; Sleep, Low Exercise Remain Concerns

life-saving-marthas-rule-to-expand-to-emergency-departments-across-england-what-it-means

‘Life-Saving’ Martha’s Rule To Expand To Emergency Departments Across England: What It Means

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Biotechnology company Grail's vision of detecting more than 50 cancers with one blood test may soon become a reality after it showed promise of a positive outcome with the US Food and Drug Administration staff reviewers. According to Reuters, FDA has not raised any major concerns yet about the accuracy and of the blood test, Galleri, which is designed to capture signals from more than 50 types of cancer. The promising biomedical technology seems to be closer to a positive regulatory decision.FDA's Stance On Galleri Ahead of an advisory committee meeting on September 23, FDA briefing documents were released which said that reviewers had no outstanding questions regarding its accuracy, safety, overall analytical performance, and study design.However, this does not mean the FDA has approved Galleri. External advisers will now examine whether the available evidence is sufficient to back it and approve the multi-cancer early detection test.More About GalleriAlso read: From Remdesivir To Ventilators: COVID Patients Died Due To Hospital Protocols, Claims Whistleblower NurseGalleri is a type of multi-cancer early detection (MCED) test. Instead of searching for one specific cancer, it examines and analyses DNA fragments circulating in the blood for chemical patterns linked with various cancers.If the test detects a cancer signal, it also attempts to predict where in the body that signal originated, helping doctors decide which diagnostic tests may be needed next.The test is not meant to replace to existing cancer screening tests such as mammograms, colon cancer screening and cervical cancer screening. It is supposed to be used with existing screening methods for faster and more accurate diagnoses. One Question Still RemainsAlso read: LSD-Based Treatment Clears Second Phase 3 Trial: Could It Be The First New GAD Drug In 2 Decades?No multi-cancer detection test is currently FDA-authorised in the US. Some are available as laboratory-developed tests, but they do not undergo the same premarket approval process.Grail submitted Galleri for FDA premarket approval in January 2026. The application includes data from PATHFINDER 2, a US study involving more than 25,000 participants, as well as data from the large NHS-Galleri trial in the UK.The FDA's latest briefing documents describe the test as having a favourable benefit-risk profile, but advisers have been asked to consider an important question before making their decision. The question is does detecting a cancer signal translate into meaningful clinical benefit for patients? It's important as finding more cancers is not automatically the same as saving more lives.Galleri Has Also Faced Questions About Early Detection            In February, Grail reported that its large UK NHS-Galleri trial did not significantly reduce the combined rate of stage III and IV cancers, the study's primary endpoint, across three screening rounds.Later analyses reported by Grail found reductions in stage IV diagnoses during screening rounds that were held later, but the company also acknowledged that the trial did not show a statistically significant reduction in the combined primary endpoint of stage III and IV cancers.This is why the FDA's question about whether Galleri should be considered an “early detection” test is particularly crucial.The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review the application on September 23. The panel's recommendation will help inform the FDA. If authorised, Galleri could become the first FDA-authorised multi-cancer detection test in the US.

blood test that could detect 50+ cancers closer to approval as fda raises no major concerns about its accuracy

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.